Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3- yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist

Psychopharmacology

Volumn 227, Issue 1, 2013, Pages 1-17

  Boess, Frank G ^a,d   De Vry, Jean ^a   Erb, Christina ^a,e   Flessner, Timo ^a   Hendrix, Martin ^a   Luithle, Joachim ^a   Methfessel, Christoph ^b   Schnizler, Katrin ^b,f   Van Der Staay, F Josef ^a,g   Van Kampen, Marja ^a,h   Wiese, Welf Burkhard ^b,c   König, Gerhard ^a  

^a BAYER PHARMA AG   (Germany)

^b BAYER AG   (Germany)

^c BAYER CROPSCIENCE AG   (Germany)

^d LILLY DEUTSCHLAND GMBH   (Germany)

^e BIOTEST AG   (Germany)

^f UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^g UTRECHT UNIVERSITY   (Netherlands)

^h UCB PHARMA   (Belgium)

Author keywords

7 nAChR agonist; Abuse liability; EVP 5141; Morris water maze; Object recognition; Passive avoidance; Radioligand binding; Social recognition; Working memory; Xenopus oocytes

Indexed keywords

BUNGAROTOXIN RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; N [1 AZABICYCLO[2.2.2]OCT 3 YL] 6 CHINOLINCARBOXAMIDE; NICOTINIC RECEPTOR ALPHA4BETA2; SEROTONIN 3 ANTAGONIST; SEROTONIN 3 RECEPTOR; UNCLASSIFIED DRUG;

AGING; AMNESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; IN VITRO STUDY; MALE; MAZE TEST; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR AFFINITY; SOCIAL INTERACTION; SPATIAL MEMORY; TASK PERFORMANCE; WORKING MEMORY;

ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR; ANIMALS; AVOIDANCE LEARNING; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEK293 CELLS; HUMANS; MALE; MEMORY; MICE; MICE, INBRED C57BL; NICOTINIC AGONISTS; PROTEIN BINDING; QUINOLINES; QUINUCLIDINES; RATS; RATS, WISTAR; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; XENOPUS LAEVIS;

EID: 84876022941     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2933-4     Document Type: Article

References (73)

1. Addy NA, Nakijama A, Levin ED (2003) Nicotinic mechanisms of memory: effects of acute local DHβE and MLA infusions in the basolateral amygdala. Brain Res Cogn Brain Res 16:51-57
2. Arendash GW, Sengstock GJ, Sanberg PR, Kem WR (1995) Improved learning and memory in aged rats with chronic administration of the nicotinic receptor agonist GTS-21. Brain Res 674:252-259
3. Bitner RS, Bunnelle WH, Anderson DJ, Briggs CA, Buccafusco J, Curzon P, Decker MW, Frost JM, Gronlien JH, Gubbins E, Li J, Malysz J, Markosyan S, Marsh K, Meyer MD, Nikkel AL, Radek RJ, Robb HM, Timmermann D, Sullivan JP, Gopalakrishnan M (2007) Broad-spectrum efficacy across cognitive domains by α7 nicotinic acetylcholine receptor agonism correlates with activation of ERK1/2 and CREB phosphorylation pathways. J Neurosci 27:10578-10587
4. Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M (2010) In vivo pharmacological characterization of a novel selective α7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease. J Pharmacol Exp Ther 334:875-886
5. Biton B, Bergis OE, Galli F, Nedelec A, Lochead AW, Jegham S, Godet D, Lanneau C, Santamaria R, Chesney F, Léonardon J, Granger P, Debono MW, Bohme GA, Sgard F, Besnard F, Graham D, Coste A, Oblin A, Curet O, Vigé X, Voltz C, Rouquier L, Souilhac J, Santucci V, Gueudet C, Françon D, Steinberg R, Griebel G, Oury-Donat F, George P, Avenet P, Scatton B (2007) SSR180711, a novel selective α7 nicotinic receptor partial agonist: (I) binding and functional profile. Neuropsychopharmacology 32:1-16
6. Boccia MM, Blake MG, Krawczyk MC, Baratti CM (2010) Hippocampal α7 nicotinic receptors modulate memory reconsolidation of an inhibitory avoidance task in mice. Neuroscience 171:531-543
7. Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay F-J, van Kampen M, Wiese WB, Koenig G (2007) The novel α7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2- carboxamide improves working and recognition memory in rodents. J Pharmacol Exp Ther 321:716-725
8. Brioni JD, Kim DJ, O'Neill AB (1996) Nicotine cue: lack of effect of the alpha 7 nicotinic receptor antagonist methyllycaconitine. Eur J Pharmacol 301:1-5
9. Cachelin AB, Rust G (1994) Unusual pharmacology of (+)-tubocurarine with rat neuronal nicotinic acetylcholine receptors containing beta 4 subunits. Mol Pharmacol 46:1168-1174
10. Chen L, Yamada K, Nabeshima T, Sokabe M (2006) α7 nicotinic acetylcholine receptor as a target to rescue deficit in hippocampal LTP induction in β-amyloid infused rats. Neuropharmacology 50:254-268
11. 125I]-α-bungarotoxin. J Neurosci 5:1307-1315
12. Colpaert FC (1982) The pharmacological specificity of opiate drug discrimination. In: Colpaert FC, Slangen JL (eds) Drug discrimination: applications in CNS pharmacology. Elsevier Biomedical, Amsterdam, pp 3-16
13. Curzon P, Anderson DJ, Nikkel AL, Fox GB, Gopalakrishnan M, Decker MW, Bitner RS (2006) Antisense knockdown of the rat α7 nicotinic acetylcholine receptor produces spatial memory impairment. Neurosci Lett 410:15-19
14. 1A receptor agonist BAY × 3702 in the rat. Eur J Pharmacol 357:1-8
15. Decker MW, Meyer MD, Sullivan JP (2001) The therapeutic potential of nicotinic receptor agonists for pain control. Expert Opin Investig Drugs 10:1819-1830
16. Dodart JC, Mathis C, Ungerer A (1997) Scopolamine-induced deficits in a two-trial object recognition task in mice. NeuroReport 8:1173-1178
17. Dziewczapolski G, Glogowski CM, Masliah E, Heinemann SF (2009) Deletion of the α7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer's disease. J Neurosci 29:8805-8815
18. Epping-Jordan MP, Picciotto MR, Changeux J-P, Pich EM (1999) Assessment of nicotinic acetylcholine receptor subunit contributions to nicotine self-administration in mutant mice. Psychopharmacology 147:25-26
19. Felix R, Levin ED (1997) Nicotinic antagonist administration into the ventral hippocampus and spatial working memory in rats. Neuroscience 81:1009-1017
20. Fernandes C, Hoyle E, Dempster E, Schalkwyk LC, Collier DA (2006) Performance deficit of α7 nicotinic receptor knockout mice in a delayed matching-to-place task suggests a mild impairment of working/episodic-like memory. Genes Brain Behav 5:433-440
21. Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, Hoyer D (2009) The selective nicotinic acetylcholine receptor α7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain. Neuropharmacology 56:254-263
22. Gommans J, Stolerman IP, Shoaib M (2000) Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6 J mice. Neuropharmacology 39:2840-2847
23. Gotti C, Zoli M, Clementi F (2006) Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci 27:482-491
24. 7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J Pharmacol Exp Ther 294:1112-1119
25. Hashimoto K, Ishima T, Fujita Y, Matsuo M, Kobashi T, Takahagi M, Tsukada H, Iyo M (2008) Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711. Biol Psychiatry 63:92-97
26. Hauser TA, Kucinski A, Jordan KG, Gatto GJ, Wersinger SR, Hesse RA, Stachowiak EK, Stachowiak MK, Papke RL, Lippiello PM, Bencherif M (2009) TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. Biochem Pharmacol 78:803-812
27. 1-42-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of α7 neuronal nicotinic acetylcholine receptor ligands. Brain Res 1151:227-235
28. Kaiser F, Hudzik T, Borrelli A, Awere S, Cramer C, Widzowski D (1998) AR-R 17779, a selective α7 nicotinic agonist, has anxiolytic and sensory gating-enhancing properties and reduced nicotine-like side-effects. Soc Neurosci Abstr 24:832
29. Kem WR (2000) The brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res 113:169-181
30. King SL, Marks MJ, Grady SR, Caldarone BJ, Koren AO, Mukhin AG, Collins AC, Picciotto MR (2003) Conditional expression in corticothalamic efferents reveals a developmental role for nicotinic acetylcholine receptors in modulation of passive avoidance behavior. J Neurosci 23:3837-3843
31. Kitagawa H, Takenouchi T, Azuma R, Wesnes KA, Kramer WG, Clody DE, Burnett AL (2003) Safety, pharmacokinetics, and effects on cognitive function of multiple doses of GTS-21 in healthy, male volunteers. Neuropsychopharmacology 28:542-551
32. Köhler CA, da Silva WC, Benetti F, Bonini JS (2011) Histaminergic mechanisms for modulation of memory systems. Neural Plast 2011:328602
33. Lagostena L, Trocme-Thibierge C, Morain P, Cherubini E (2008) The partial α7 nicotine acetylcholine receptor agonist S 24795 enhances long-term potentiation at CA3-CA1 synapses in the adult mouse hippocampus. Neuropharmacology 54:676-685
34. Levin ED, Bettegowda C, Blosser J, Gordon J (1999) AR-R17779, an alpha7 nicotinic agonist, improves learning and memory in rats. Behav Pharmacol 10:675-680
35. Levin ED, McClernon FJ, Rezvani AH (2006) Nicotinic effects on cognitive function: behavioral characterization, pharmacological specification, and anatomic localization. Psychopharmacology 184:523-539
36. Liu Q, Huang Y, Xue F, Simard A, DeChon J, Li G, Zhang J, Lucero L, Wang M, Sierks M, Hu G, Chang Y, Lukas RJ, Wu J (2009) A novel nicotinic acetylcholine receptor subtype in basal forebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29:918-929
37. Marquis KL, Comery TA, Jow F, Navarra RL, Grauer SM, Pulicicchio C, Kelley C, Brennan JA, Roncarati R, Scali C, Haydar S, Ghiron C, Terstappen GC, Dunlop J (2011) Preclinical assessment of an adjunctive treatment approach for cognitive impairment associated with schizophrenia using the alpha7 nicotinic acetylcholine receptor agonist WYE-103914/SEN34625. Psychopharmacology 218:635-647
38. Marubio LM, Paylor R (2004) Impaired passive avoidance learning in mice lacking central neuronal nicotinic acetylcholine receptors. Neuroscience 129:575-582
39. Merlo Pich E, Chiamulera C, Carboni L (1999) Molecular mechanisms of the positive reinforcing effect of nicotine. Behav Pharmacol 10:587-596
40. Morris R (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11:47-60
41. Mundy WR, Barone S, Tilson HA (1990) Neurotoxic lesions of the nucleus basalis induced by colchicine: effects on spatial navigation in the water maze. Brain Res 512:221-228
42. Nott A, Levin ED (2006) Dorsal hippocampal α7 and α4β2 nicotinic receptors and memory. Brain Res 1081:72-78
43. Oglesby MW, Epping-Jordan MP, Merlo-Pich E, Picciotto MR, Changeux JP (1998) Attenuated nicotine discrimination in mice lacking high affinity nicotine receptors. Soc Neurosci Abstr 24:1196
44. Paterson D, Nordberg A (2000) Neuronal nicotinic receptors in the human brain. Prog Neurobiol 61:75-111
45. Paylor R, Nguyen M, Crawley JN, Patrick J, Beaudet A, Orr-Urtreger A (1998) α7 nicotinic receptor subunits are not necessary for hippocampal-dependent learning or sensorimotor gating: a behavioral characterization of Acra7-deficient mice. Learn Mem 5:302-316
46. Picciotto MR, Zoli M, Léna C, Bessis A, Lallemand Y, LeNovère N, Vincent P, Pich EM, Brûlet P, Changeux J-P (1995) Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptor in the brain. Nature 374:65-67
47. Picciotto MR, Zoli M, Rimondini R, Léna C, Marubio LM, Pich EM, Fuxe K, Changeux JP (1998) Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature 391:173-177
48. Pichat P, Bergis OE, Terranova J-P, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B (2007) SSR180711, a novel selective α7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17-34
49. Prickaerts J, ŞIk A, van der Staay FJ, de Vente J, Blokland A (2005) Dissociable effects of acetylcholinesterase inhibitors and phosphodiesterase type 5 inhibitors on object recognition memory: acquisition versus consolidation. Psychopharmacology 177:381-390
50. Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OAH, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, König G (2012) EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors. Neuropharmacology 62:1099-1110
51. Puzzo D, Privitera L, Leznik E, Fà M, Staniszewski A, Palmeri A, Arancio O (2008) Picomolar amyloid-β positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 28:14537-14545
52. Ren K, Thinschmidt J, Liu J, Ai L, Papke RL, King MA, Hughes JA, Meyer EM (2007) α7 nicotinic receptor gene delivery into mouse hippocampal neurons leads to functional receptor expression, improved spatial memory-related performance, and tau hyperphosphorylation. Neuroscience 145:314-322
53. Roncarati R, Scali C, Comery TA, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC (2009) Procognitive and neuroprotective activity of a novel α7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. J Pharmacol Exp Ther 329:459-468
54. Shoaib M, Zubaran C, Stolerman IP (2000) Antagonism of stimulus properties of nicotine by dihydro-β-erythroidine (DHβE) in rats. Psychopharmacology 149:140-146
55. Shoaib M, Gommans J, Morley A, Stolerman IP, Grailhe R, Changeux J-P (2002) The role of nicotinic receptor beta-2 subunits in nicotine discrimination and conditioned taste aversion. Neuropharmacology 42:530-539
56. Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P, Tricklebank M (2007) Ligands selective for α4β2 but not α3β4 or α7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology 190:157-170
57. Stokes C, Porter Papke JK, Horenstein NA, Kem WR, McCormack TJ, Papke RL (2004) The structural basis for GTS-21 selectivity between human and rat nicotinic α7 receptors. Mol Pharmacol 66:14-24
58. Stolerman IP, Naylor C, Elmer GI, Goldberg SR (1999) Discrimination and self-administration of nicotine by inbred strains of mice. Psychopharmacology 141:297-306
59. Stolerman IP, Chamberlain S, Bizarro L, Fernandes C, Schalkwyk L (2004) The role of nicotinic receptor α7 subunits in nicotine discrimination. Neuropharmacology 46:363-371
60. Sydserff S, Sutton EJ, Song D, Quirk MC, Maciag C, Li C, Jonak G, Gurley D, Gordon JC, Christian EP, Doherty JJ, Hudzik T, Johnson E, Mrzljak L, Piser T, Smagin GN, Wang Y, Widzowski D, Smith JS (2009) Selective α7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. Biochem Pharmacol 78:880-888
61. Tatsumi R, Fujio M, Takanashi S, Numata A, Katayama J, Satoh H, Shiigi Y, Maeda J, Kuriyama M, Horikawa T, Murozono T, Hashimoto K, Tanaka H (2006) (R)-3′-(3-Methylbenzo[b]thiophen-5-yl)spiro[1-azabicyclo[2,2,2]octane-3, 5′-oxazolidin]-2′-one, a novel and potent α7 nicotinic acetylcholine receptor partial agonist displays cognitive enhancing properties. J Med Chem 49:4374-4383
62. Timmermann DB, Grønlien JH, Kohlhaas KL, Nielsen EØ, Dam E, Jørgensen TD, Ahring PK, Peters D, Holst D, Chrsitensen JK, Malysz J, Briggs CA, Gopalakrishnan M, Olsen GM (2007) An allosteric modulator of the α7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. J Pharmacol Exp Ther 323:294-307
63. Tinsley CJ, Fontaine-Palmer NS, Vincent M, Endean EP, Aggleton JP, Brown MW, Warburton EC (2011) Differing time dependencies of object recognition memory impairments produced by nicotinic and muscarinic cholinergic antagonism in perirhinal cortex. Learn Mem 18:484-492
64. Toyohara J, Hashimoto K (2010) α7 nicotinic receptor agonists: potential therapeutic drugs for treatment of cognitive impairments in schizophrenia and Alzheimer's disease. Open Med Chem J 4:37-56
65. Tribollet E, Bertrand D, Marguerat A, Raggenbass M (2004) Comparative distribution of nicotinic receptor subtypes during development, adulthood and aging: an autoradiographic study in the rat brain. Neuroscience 124:405-420
66. van der Staay FJ (2000) The study of behavioral dysfunctions: an evaluation of selected animal models. Dissertation, Graduate School of Behavioral and Cognitive Neurosciences (BCN). University Groningen, The Netherlands, (ISBN 90-367-1195-9), http://irs.ub.rug.nl/ppn/322034345
67. van der Staay FJ (2006) Two months makes a difference in spatial orientation learning in very old FBNF1 rats. Physiol Behav 87:659-665
68. van Kampen M, Selbach K, Schneider R, Schiegel E, Boess F, Schreiber R (2004) AR-R 17779 improves social recognition in rats by activation of nicotinic α7 receptors. Psychopharmacology 172:375-383
69. Wallace TL, Callahan PM, Tehim A, Bertrand D, Tombaugh G, Wang S, Xie W, Rowe WB, Ong V, Graham E, Terry AV Jr, Rodefer JS, Herbert B, Murray M, Porter R, Santarelli L, Lowe DA (2011) RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther 336:242-253
70. 3 receptors: role in disease and target of drugs. Pharmacol Ther 128:146-169
71. Whishaw IQ (1985) Formation of a place learning-set by the rat: a new paradigm for neurobehavioral studies. Physiol Behav 35:139-143
72. Wishka DG, Walker DP, Yates KM, Reitz SC, Jia S, Myers JK, Olson KL, Jacobsen EJ, Wolfe ML, Groppi VE, Hanchar AJ, Thornburgh BA, Cortes-Burgos LA, Wong EHF, Staton BA, Raub TJ, Higdon NR, Wall TM, Hurst RS, Walters RR, Hoffmann WE, Hajos M, Franklin S, Carey G, Gold LH, Cook KK, Sands SB, Zhao SX, Soglia JR, Kalgutkar AS, Arneric SP, Rogers BN (2006) Discovery of N-[(3R)-1- azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the α7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure-activity relationship. J Med Chem 49:4425-4436
73. 3A receptors confer partial agonist and antagonist properties to benzylidene analogs of anabaseine. J Pharmacol Exp Ther 317:1276-1284